Mini Review - (2022) Volume 7, Issue 10
In hospitalised patients, Staphylococcus aureus is a frequent source of serious infections. Necrotizing skin and soft tissue infections, bacteraemia, endocarditis, and pneumonia are all on the disease's spectrum. Patients who have prosthetic devices such artificial joints, cardiac support devices, and haemodialysis catheters are additionally at risk for staphylococcal infection. Additionally, S. aureus is increasingly frequently linked to both skin infections and pneumonia in hospital patients [1]. Beta lactams are a therapy option for Methicillin Sensitive Staphylococcus aureus (MSSA), which causes Staphylococcus infections, or Methicillin- Resistant Staphylococcus aureus (MRSA), which is the "gold standard" for treating severe infections. Clindamycin, bactrim , and other antibiotics are also utilised in the treatment of staphylococcal infections [2].
Despite the "gold standard" being dosed to perfection, failure rates are now rising. Vancomycin Minimum Inhibitory Concentrations (MICs) have increased, which can be A. aureus. Additionally, the creation of drugs like linezolid, daptomycin, tigecycline, and ceftaroline has been prompted by the possibility of side effects, such as nephrotoxicity linked to vancomycin. Daptomycin is regarded as a bactericidal medication, whereas linezolid is a bacterostatic. As was to be predicted, there have been cases of treatment failure even with large doses of linezolid, ceftaroline, and daptomycin that have been documented. Another factor that contributes to "collateral damage" is the use of systemic antibiotics that target S. aureus [3].
These medicines alter the bacterial flora of the host as well as S. aureus, leading to additional infection problems. The emergence of diarrhoea and a Clostridium difficile infection is the most prevalent manifestation of this. Therefore, the creation of new antimicrobial products to combat S. aureus is urgently needed.
The research Vaillant et al. offer in this edition of the Journal of Vaccine and Vaccination on "non- antibiotic" therapy is crucial for infections caused by staphylococci. S.aureus Synthesizes Protein A (SpA ), which has been shown to be responsible for a series of events that facilitate bacterial invasion of host tissue and plays a crucial role in bacterial adherence. To create SpA antibodies, the authors employed chicks. They demonstrated the antibacterial capabilities of this product by proving that the antibody could stop S. aureus from growing [4].
The use of targeted antibodies in the fight against S. aureus infections is crucial for a number of reasons, including the rise in antibiotic resistance as already mentioned, the serious side effects of prolonged, high- dose antibiotic therapy for resistant infections, and the rising number of patients who develop multiple antibiotic allergy symptoms. Additionally, it is hoped that focused therapy may lessen the chance of collateral damage and consequently C. difficile infection. It's not a novel idea to use the immune system to fend against infections [5]. Examples of the use of substances in the prevention of bacterial and viral illnesses, respectively, include oral typhoid and polio vaccinations. One of the newer methods for treating C. difficile infection is the use of monoclonal antibodies that target bacterial toxins. The oral mode of administration and non- live nature of this substance are key benefits of the authors' research.
It is important to mention one warning at this time. Although vaccine safety has been shown, a proportion of individuals claim to be allergic to eggs, which has made administering a number of vaccines to these patients difficult. A product created with a chick embryo may not be able to be used by humans due to this. But we eagerly await future advancements and the standardised use of this intriguing prospective antibacterial agent [6].
Citation: Stones, R. A New Front in the Fight Against Infection, Creation of Antimicrobial Antibodies. Med Rep Case Stud. 2022, 07(10), 001.
Received: 26-Oct-2022, Manuscript No. mrcs-22-79182; Editor assigned: 28-Oct-2022, Pre QC No. mrcs-22- 79182 (PQ); Reviewed: 08-Nov-2022, QC No. mrcs-22-79182 (Q); Revised: 10-Nov-2022, Manuscript No. mrcs-22-79182 (R); Published: 15-Nov-2022, DOI: 10.4172/2572-5130.22.7(10)1000220
Copyright: ©2022 Stones, R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
